Effect of moderate or high versus low dose daily vitamin D on COVID-19 incidence: A double-blind, parallel-group randomized clinical trial.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

However, randomized clinical trials vary in whether they find vitamin D supplementation affects COVID-19 risk.

Who Took Part

The abstract describes 2023, participants taking part.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

Recruitment occurred at UChicago Medicine or Rush University Medical Center.

How the Study Was Run

The design is described as randomized, double-blind and parallel-group.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

Groups ran in parallel: each of the participants stayed in one arm throughout.

The primary outcome was time from randomization to COVID-19 infection.

What Was Measured

Topics PubMed links to this paper include Vitamin D, COVID-19, Dietary Supplements, SARS-CoV-2, Incidence, Vitamins and Vitamin D Deficiency.

Author keywords: Nutrition and Supplementation.

What This Means in Plain Language

The paper is a randomized, double-blind and parallel-group study of Vitamin D, K2, Magnesium and Zinc in 2023, participants.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2026 (Clinical nutrition (Edinburgh, Scotland)), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.